The purpose of the Core C Biostatistics is to assure that studies conducted through this P01 to develop novel therapeutic strategies in myeloid malignancies are conceptualized under robust principles of statistical design and are analyzed appropriately.
Specific Aim 1. To provide biostatistical collaboration for clinical research protocols. Biologically motivated clinical research protocols in this P01 are conducted through Core D as in vivo human experiments on behalf of the projects. Support by Core C includes all aspects of the design, conduct, analysis, and reporting of the clinical studies, as well as oversight of the electronic data capture mechanism.
Specific Aim 2. To provide biostatistical collaboration for the laboratory research studies. This includes all aspects of the design, conduct, analysis, and reporting of such studies, as well as the association between laboratory results and clinical outcomes both in prospective clinical studies of new agents and in retrospective studies involving sequencing and identification of mutations and their associations with both clinical features of disease and with clinical outcomes. 3. To provide biostatistical collaboration for animal studies, including all aspects of the design and analysis of murine studies.
Core C Biostatistics will assure that all experiments conducted through this P01 in myeloid malignancies will have robust statistical designs and appropriate statistical analysis, to optimize our ability to identify novel therapeutic strategies and improve our understanding of the biology of myeloid malignancies.
|Townsend, Elizabeth C; Murakami, Mark A; Christodoulou, Alexandra et al. (2016) The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 29:574-86|
|Arreba-Tutusaus, P; Mack, T S; Bullinger, L et al. (2016) Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia 30:1220-5|
|Tanaka, Minoru; Roberts, Justin M; Seo, Hyuk-Soo et al. (2016) Design and characterization of bivalent BET inhibitors. Nat Chem Biol 12:1089-1096|
|Wu, H; Hu, C; Wang, A et al. (2016) Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia 30:173-81|
|Wu, H; Hu, C; Wang, A et al. (2016) Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 30:754-7|
|Puram, Rishi V; Kowalczyk, Monika S; de Boer, Carl G et al. (2016) Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell 165:303-16|
|Brien, Gerard L; Valerio, Daria G; Armstrong, Scott A (2016) Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell 29:464-76|
|Zhu, Nan; Chen, Mo; Eng, Rowena et al. (2016) MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest 126:997-1011|
|Schneider, Rebekka K; Schenone, Monica; Ferreira, Monica Ventura et al. (2016) Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med 22:288-97|
|Hatcher, John M; Weisberg, Ellen; Sim, Taebo et al. (2016) Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett 7:476-81|
Showing the most recent 10 out of 280 publications